HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lester, L. R. Articles by Hak, E. B. Search for Related Content PubMed PubMed Citation Articles by Lester, L. R. Articles by Hak, E. B.

LINDSAY R. LESTER, PHARM.D., is Pediatric Pharmacotherapy Resident, Le Bonheur Children’s Medical Center, Memphis, TN. CATHERINE M. CRILL, PHARM.D., is Assistant Professor of Pharmacy and Pediatrics; and EMILY B. HAK, PHARM.D., is Associate Professor of Pharmacy, Pharmacology, and Pediatrics, The University of Tennessee Health Science Center, Memphis.

Address correspondence to Dr. Crill at The University of Tennessee Health Science Center, 26 South Dunlap, Suite 210, Memphis, TN 38163 (ccrill{at}utmem.edu).

Purpose. The technical issues surrounding the use of albumin in parenteral nutrient (PN) solutions are reviewed. Summary. Five criteria have been suggested to determine which compounds are optimal for addition to PN solutions: (1) stable dosage regimen over 24 hours, (2) pharmacokinetic profile supporting a 24-hour infusion, (3) stable PN solution infusion rate, (4) documented physical stability over at least 24 hours, and (5) documented chemical stability over at least 24 hours. Albumin is stable in solutions containing dextrose and electrolytes, but its stability in solutions containing dextrose and amino acids has not been evaluated. Signs of precipitation and flocculation have been reported when albumin and zinc chloride were added simultaneously to a two-in-one PN solution. Similar to hemoglobin, albumin is nonenzymatically glycosylated in vivo. One of the most common complications associated with the use of PN solutions is catheter-related bloodstream infection. Albumin 25 g/L in two-in-one PN solutions has been shown to clog 0.2-µm filters. Albumin products have historically contained a large amount of aluminum contamination; thus, the addition of albumin to PN solutions would further contribute to accumulated aluminum contaminants in patients receiving PN therapy, particularly neonates. Conclusion. Based on the available evidence, the addition of albumin to PN solutions cannot be recommended. The potential for complications due to infection and physical and chemical incompatibility and instability exists. Adding albumin to PN solutions can affect infusion flow rates and pump pressures, thereby compromising the appropriate delivery of PN solutions to patients. The theoretical risk of glycosylation and related complications outweigh potential benefits of albumin administration via PN solution. Index terms: Albumin; Aluminum; Amino acids; Caloric agents; Contamination; Dextrose; Dosage; Electrolytes; Flocculation; Flow; Incompatibilities; Minerals; Nutrition; Pediatrics; Pharmacokinetics; Precipitation; Proteins; Rational therapy; Stability; Storage; Toxicity; Zinc chloride